Le Lézard
Classified in: Health
Subject: SVY

PharmaFocus: Visual Analysis of Immuno-Oncology Development and Opportunities

NEW YORK, Oct. 6, 2017 /PRNewswire/ -- PharmaFocus: Visual Analysis of Immuno-Oncology Development and Opportunities


Read the full report: https://www.reportlinker.com/p05134501

Immuno-Oncology (IO) is uniquely positioned to become the fifth pillar of cancer treatment alongside surgery, radiotherapy, chemotherapy, and other targeted treatments. In order to assist our clients with navigating the burgeoning amount information arising as a result of the rapidly growing field of IO clinical research, GlobalData is offering a comprehensive analysis of both pipeline and marketed active immunity IO therapies.

Key Topics Covered -
- Immune Checkpoint Modulators - Trends in Clinical Trial Development
- Competitive Assessment of Marketed PD-(L)1 Checkpoint Modulators
- Emergence of New Immune Checkpoint Targets
- Clinical and Commercial Opportunities for Highly Anticipated CAR Cell Therapies
- Cell Vaccines: Steady Development Stimulated by Prior IO Success
- Promising IO-IO Combinations Utilizing Oncolytic Viruses

Reasons to buy
- The PharmaFocus consists of a highly-visual slide deck that is intended to facilitate the dissemination of aggregated data and insights from analyses of over 800 IO products that are either marketed or in Phase I-III of clinical development.
- Types of graphical analyses include - Cumulative Plots, Aggregated Bubble Plots, Pie Charts, Matrix Analyses
- Unique, actionable insights applicable to IO drugs in five major categories: Immune Checkpoint Modulators, Cellular Immunotherapies, Oncolytic Viruses, Peptide Vaccines, and Bispecific T-Cell Engagers are provided in this report.
- Analysis of over 4000 clinical trials enrolling patients with 18 solid tumors and eight hematological cancers are included.

Read the full report: https://www.reportlinker.com/p05134501

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.


Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

These press releases may also interest you

at 07:03
NeoGenomics, Inc. , a leading provider of cancer-focused genetic testing services, announced today the appointment of George Cardoza as President of the Pharma Services Division and Sharon Virag as Chief Financial Officer. Ms. Virag will succeed...

at 07:03
Oncolytics Biotech® Inc. , a biotech company developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus creating an inflamed phenotype, today announced that Grey Wilkinson, Ph.D., scientist of Translational Medicine at...

at 07:03
Trillium Therapeutics Inc. , an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted an Orphan Drug...

at 07:00
Cipher Pharmaceuticals Inc. and Cardiome Pharma Corp. , today announced their entry into a definitive arrangement agreement pursuant to which Cipher will acquire the Canadian business portfolio of...

at 07:00
Boston Scientific Corporation announced real-world data from the TRUE-HD study during a late-breaking clinical trial session today at the annual congress of the European Heart Rhythm Association (EHRA) in Barcelona, Spain. The data demonstrated the...

at 07:00
Cressey & Company LP ("Cressey & Company" or the "Firm"), a healthcare-focused private investment firm, has announced that Andy Hurd, an experienced healthcare and technology executive, has joined the Firm as an Operating Partner. Mr. Hurd's...

News published on 6 october 2017 at 11:12 and distributed by: